2. PROTAC Epigenetics Cell Cycle/DNA Damage Apoptosis
  3. PROTACs PARP Apoptosis
  4. PROTAC PARP2 degrader-1

PROTAC PARP2 degrader-1 is an orally active PARP2 PROTAC degrader with a DC50 of 2 μM. PROTAC PARP2 degrader-1 potently inhibits the enzymatic activities of PARP1 (IC50 = 2.74 nM) and PARP2 (IC50 = 0.32 nM), with approximately 10-fold higher selectivity for PARP2. PROTAC PARP2 degrader-1 induces cell cycle arrest and apoptosis, and exhibits significant anti-tumor efficacy in mouse models. PROTAC PARP2 degrader-1 can be used for the research of triple-negative breast cancer.
(Pink: PARP-2 ligand (HY-75706); Blue: Cereblon ligand (HY-131385); Black: linker (HY-W089232)).

For research use only. We do not sell to patients.

PROTAC PARP2 degrader-1

PROTAC PARP2 degrader-1 Chemical Structure

CAS No. : 2925182-32-5

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

PROTAC PARP2 degrader-1 Related Antibodies

Top Publications Citing Use of Products

View All PROTACs Isoform Specific Products:

View All Isoforms
von Hippel-Lindau (VHL) Cereblon MDM2 cIAP1

View All PARP Isoform Specific Products:

View All Isoforms
PARP PARP1 PARP2 PARP3 PARP4 TNKS1/PARP5A TNKS2/PARP5B PARP7 PARP10 PARP14 PARP15 PARP12 PARP16

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

PROTAC PARP2 degrader-1 is an orally active PARP2 PROTAC degrader with a DC50 of 2 μM. PROTAC PARP2 degrader-1 potently inhibits the enzymatic activities of PARP1 (IC50 = 2.74 nM) and PARP2 (IC50 = 0.32 nM), with approximately 10-fold higher selectivity for PARP2. PROTAC PARP2 degrader-1 induces cell cycle arrest and apoptosis, and exhibits significant anti-tumor efficacy in mouse models. PROTAC PARP2 degrader-1 can be used for the research of triple-negative breast cancer[1]. (Pink: PARP-2 ligand (HY-75706); Blue: Cereblon ligand (HY-131385); Black: linker (HY-W089232)).

IC50 & Target[1]

PARP-2

2 μM (DC50)

Cereblon

 

Cellular Effect
Cell Line Type Value Description References
CAPAN-1 IC50
0.061 μM
Compound: C8
Antiproliferative activity against human BRCA2 -/- CAPAN-1 cells assessed as reduction in cell viability incubated for 5 to 10 days by MTT assay
Antiproliferative activity against human BRCA2 -/- CAPAN-1 cells assessed as reduction in cell viability incubated for 5 to 10 days by MTT assay
[PMID: 35430559]
In Vitro

PROTAC PARP2 degrader-1 (Compound C8) (5-10 days) potently inhibits the proliferation of MDA-MB-436, Capan-1, MDA-MB-468 and MDA-MB-231 cells, with IC50 values of 0.026 μM, 0.061 μM, 0.69 μM and 0.53 μM, respectively. Moreover, its activity in non-BRCA-mutant TNBC cells is significantly higher than that of Olaparib[1].
PROTAC PARP2 degrader-1 (C8) (0.5 μM; 24 h) selectively degrades nuclear PARP2 in MDA-MB-231 cells without affecting the level of cytoplasmic PARP2[1].
PROTAC PARP2 degrader-1 (0.312-5 μM; 14 days) potently and dose-dependently inhibits colony formation of MDA-MB-231 cells[1].
PROTAC PARP2 degrader-1 (0.156-2.5 μM; 24-48 h) induces dose-dependent G2/M cell cycle arrest in MDA-MB-436 and MDA-MB-231 cells[1].
PROTAC PARP2 degrader-1 (C8) (0.312-5 μM; 48-72 h) induces dose-dependent apoptosis in MDA-MB-436 and MDA-MB-231 cells, and [the sentence is incomplete in the source text, maintained as is] compared with Olaparib[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PROTAC PARP2 degrader-1 Related Antibodies

Immunofluorescence[1]

Cell Line: MDA-MB-231 (wild-type) TNBC cells
Concentration: 0.5 μM
Incubation Time: 24 h
Result: Resulted in nearly complete degradation of nuclear PARP2, while cytoplasmic PARP2 fluorescence remained unchanged.
Showed no effect on PARP2 levels in either compartment when compared to inactive analog C8-M.

Cell Proliferation Assay[1]

Cell Line: MDA-MB-231 (wild-type) TNBC cells
Concentration: 0.312, 0.625, 1.25, 2.5 and 5 μM
Incubation Time: 14 days
Result: Reduced colony formation in a dose-dependent manner, with significant inhibition observed at concentrations as low as 0.312 μM.
Nearly completely abolished colony formation at 1.25 μM and higher concentrations.

Cell Cycle Analysis[1]

Cell Line: MDA-MB-436 (BRCA1-/-) breast cancer cells, MDA-MB-231 (wild-type) TNBC cells
Concentration: 0.156, 0.312, 0.625, 1.25, 2.52.5 μM
Incubation Time: 24 h (MDA-MB-231); 48 h (MDA-MB-436)
Result: Induced a dose-dependent G2/M cell cycle arrest in both cell lines, with a significantly greater arrest compared to Olaparib at equivalent concentrations.
Increased G2/M phase distribution in MDA-MB-231 cells from ~26% in controls to ~37% at 1.25 μM C8.

Apoptosis Analysis[1]

Cell Line: MDA-MB-436 (BRCA1-/-) breast cancer cells, MDA-MB-231 (wild-type) TNBC cells
Concentration: 0.312, 0.625, 1.25, 2.5 and 5 μM
Incubation Time: 48 h (MDA-MB-231); 72 h (MDA-MB-436)
Result: Induced dose-dependent apoptosis in both cell lines, with a more pronounced effect in MDA-MB-231 cells.
Reached ~90% apoptosis in MDA-MB-231 cells at 5 μM C8, compared to ~48% with Olaparib.
In Vivo

PROTAC PARP2 degrader-1 (Compound C8) (12.5-100 mg/kg; ig, ip; 21 days) dose-dependently suppresses MDA-MB-231 TNBC xenograft growth[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude (female, 5-6 weeks old, subcutaneous xenograft model)[1]
Dosage: 100 mg/kg (ig); 12.5 mg/kg (ip); 25 mg/kg (ip)
Administration: ig; ip; daily; 21 days
Result: Achieved tumor growth inhibition (TGI) of 63.5% at 100 mg/kg ig.
Achieved tumor growth inhibition (TGI) of 82.9% at 12.5 mg/kg ip.
Achieved tumor growth inhibition (TGI) of 98.3% at 25 mg/kg ip.
Caused no obvious weight loss, morbidity, or mortality during 21-day treatment.
Showed no obvious histopathological lesions in heart, liver, spleen, kidney, and lung at 25 mg/kg ip.
Molecular Weight

801.35

Formula

C43H50ClFN6O6
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C1NN=C(CC2=CC=C(C(C(N3CCN(CC3)C(CCCCCCCCCNC(COC4=CC=C5C(CCCN5C(CCl)=O)=C4)=O)=O)=O)=C2)F)C6=C1C=CC=C6
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (124.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.2479 mL 6.2395 mL 12.4789 mL
5 mM 0.2496 mL 1.2479 mL 2.4958 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (3.12 mM); Suspended solution

    This protocol yields a suspended solution of ≥ 2.5 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (3.12 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.2479 mL 6.2395 mL 12.4789 mL 31.1974 mL
5 mM 0.2496 mL 1.2479 mL 2.4958 mL 6.2395 mL
10 mM 0.1248 mL 0.6239 mL 1.2479 mL 3.1197 mL
15 mM 0.0832 mL 0.4160 mL 0.8319 mL 2.0798 mL
20 mM 0.0624 mL 0.3120 mL 0.6239 mL 1.5599 mL
25 mM 0.0499 mL 0.2496 mL 0.4992 mL 1.2479 mL
30 mM 0.0416 mL 0.2080 mL 0.4160 mL 1.0399 mL
40 mM 0.0312 mL 0.1560 mL 0.3120 mL 0.7799 mL
50 mM 0.0250 mL 0.1248 mL 0.2496 mL 0.6239 mL
60 mM 0.0208 mL 0.1040 mL 0.2080 mL 0.5200 mL
80 mM 0.0156 mL 0.0780 mL 0.1560 mL 0.3900 mL
100 mM 0.0125 mL 0.0624 mL 0.1248 mL 0.3120 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

PROTAC PARP2 degrader-1 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

PROTAC PARP2 degrader-12925182-32-5PROTACsPARPApoptosispoly ADP ribose polymerase MDA-MB-231PARP2triple-negative breast cancerPARP1MDA-MB-436Capan-1G2/M cell cycle arrestMDA-MB-468DCAF16proteasomeInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PROTAC PARP2 degrader-1
Cat. No.:
HY-183013
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.